Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501654 | 0.89 | ALDH1A1 (0.46) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL29128071 | 0.87 | NPC1 (0.56) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL30231055 | 0.85 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL694449 | 0.85 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL12788047 | 0.84 | CA1 (0.53) | ALDH1A1SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL838914 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL17522159 | 0.83 | ALDH1A1 (0.56) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5801989 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL7578086 | 0.82 | ALDH1A1 (0.51) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL27341803 | 0.82 | ALDH1A1 (0.51) | ALDH1A1TSHRCYP1A2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| EP-4516777-A2 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| CN-115315421-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2022-11-08 | — | — | CN | disclosed |
| EP-4074376-A1 | COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION | Nippon Shinyaku Co., Ltd. (JP) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021117846-A1 | COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION | 日本新薬株式会社 | 2021-06-17 | — | — | WO | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | ALDH1A1 1938/4885TSHR 2443/4885CYP1A2 4206/4885 |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | PDGFRB, PDGFRA, PDGFA | ALDH1A1 2989/4885TSHR 2569/4885CYP1A2 4378/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | ALDH1A1 3073/4885TSHR 1458/4885CYP1A2 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.